ArticleCancer medicine2026
Cancer Risk Among Young Adults With Clinically Diagnosed Fatty Liver Disease: A Nationwide Cohort Study in South Korea.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) is a growing public health concern, particularly among young adults. While MASLD is a well-established risk factor for liver-related complications, growing evidence suggests an association with several extrahepatic cancers. However, data regarding cancer risk among young adults with MASLD remain limited. This study investigates the association between MASLD and cancer risk in young adults in South Korea.
methodsA nationwide cohort study was conducted using the Korean National Health Insurance Service database, including individuals aged 20-39 years who underwent health screenings (2004-2007). Clinically diagnosed fatty liver disease was identified using ICD-10 code K76.0, and incident cancers were identified using ICD-10 malignant neoplasm codes recorded in the National Health Insurance Service claims database through 2022. Cox proportional hazards models estimated hazard ratios (HRs) for cancer risk, adjusting for confounders.
resultsAmong 4,094,241 participants, 254,897 (6.22%) had clinically diagnosed fatty liver disease. Clinically diagnosed fatty liver disease was significantly associated with increased all-cancer incidence in both men (HR: 1.48, 95% CI 1.45-1.51) and women (HR: 1.23, 95% CI 1.20-1.27). The highest risks were observed for liver cancer (men, HR: 2.39, 95% CI 2.28-2.50, women, HR: 2.88, 95% CI 2.56-3.23), thyroid cancer (men, HR: 1.49, 95% CI 1.43-1.55, women, HR: 1.18, 95% CI 1.13-1.24). BMI-based fatty liver disease (BMI < 25 kg/m
conclusionsClinically diagnosed fatty liver disease in young adults was associated with a higher risk of both hepatic and extrahepatic cancers. Further studies are needed to determine appropriate risk-stratified prevention and surveillance strategies in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.